TITLE

Positioning of HIV-protease inhibitors in clinical practice

AUTHOR(S)

Andreoni, M.; Perno, C. F.

PUB. DATE

January 2012

SOURCE

European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 1, p10

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

The availability of more than 20 drugs for the treatment of HIV infection, and the success of the current antiretroviral regimens, should not overlook the difficulty of longterm maintaining the control of viral replication. The therapy needs to be continued for decades, if not for lifetime, and there are clear evidences that, even in patients fully suppressed for many years, HIV starts again its replication cycles in case antiviral pressure is removed. The development of resistance is a natural event at the time of virological failure, that needs to be taken into account in the global strategy against HIV in each particular patient. Taking all together, therapeutic regiments must be embedded, since the beginning, in a long-term strategy whose main task is the stable control of the replication of HIV. To do so, the choice of the first antiviral regimen has to be highly appropriate to keep the virus in check, and at the same time maintain future therapeutic options. Change of therapy at the time of failure has to be also appropriate, in term of timing, diagnostic strategy, and selection of drugs. Under these circumstances, the use of protease inhibitors in the first line acquires a strong rationale, that balances the greater pure potency of non-nucleoside reverse transcriptase inhibitors (NNRTI), and makes them a valuable options for many patients that need to start antiviral therapy.

ACCESSION #

73786314

 

Related Articles

• Lack of Effect of Doxycycline on Trough Concentrations of Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients. Abgrall, S.; Le Bel, J.; Lele, N.; Laouénan, C.; Eychenne, N.; Mentré, F.; Peytavin, G.; Bouchaud, O.; the VIHVO Study Group // HIV Clinical Trials;Nov/Dec2013, Vol. 14 Issue 6, p313 

  Background: Many HIV-treated patients travel to malaria-infected zones, but very few data are available on potential interactions between antiretroviral and antimalarial drugs. Method: We performed a pharmacokinetic study on the interaction of doxycycline (100 mg/d) on 2 protease inhibitors...

• Intracellular Concentrations of Non-Nucleoside Reverse Transcriptase Inhibitors and its Potential Role on Apoptosis in Peripheral Blood Mononuclear Cells.  // Journal of Antivirals & Antiretrovirals;2011, Vol. 3 Issue 2, p14 

  The article focuses on the study conducted to examine the potential role and intracellular concentrations of non-nucleoside reverse transcriptase inhibitors (NNRTIs) on apoptosis in peripheral blood mononuclear cells (PBMCs). It mentions efavirenz (EFV) and nevirapine (NVP) are the two NNRTIs...

• Enhancement of dissolution rate of Efavirenz by solid dispersion technique. Kumar, Bada Pragati; Yunoos, Mohammad; Chandana, Nala; Habeeb, Mohammad; Himaja, B. // Journal of Pharmacy Research;Dec2010, Vol. 3 Issue 12, p2840 

  Efavirenz is an HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI). It is an antiretroviral agent indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, which is not soluble in water and lower absorption in gastric fluid. In order to improve the...

• Nevirapine.  // AHFS Consumer Medication Information;Oct2019, p1 

  Nevirapine is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Nevirapine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works...

• What's New in the HIV Treatment Guidelines? Deresinski, Stan // Infectious Disease Alert;Dec2011, Vol. 31 Issue 3, p29 

  The article highlights the changes made to the "Guidelines for the Use of Antiretroviral Agents in HIV-I-Infected Adults and Adolescents." The guidelines focus on the choice of an initial regimen for antiretroviral treatment-naïve Human Immunodeficiency Virus (HIV) patients. Areas revised...

• Nucleoside-Free Boosted Double PI Regimen: Significant CD4+ T-Cell Recovery in Patients with Poor Immunologic Response Despite Virologic Suppression. Lehmann, Clara; Jung, Norma; Hofmann, Anika; Cornely, Oliver A.; Wyen, Christoph; Fätkenheuer, Gerd; Hartmann, Pia // Current HIV Research;Nov2008, Vol. 6 Issue 6, p555 

  Antiretroviral therapy in human immunodeficiency virus infection is occasionally associated with poor immunologic responses despite full suppression of viral replication. As some combinations of nucleoside analogues (NA) have been associated with paradoxical depletion of CD4+ T- cells, we...

• Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity. Agneskog, Eva; Nowak, Piotr; Maijgren Steffensson, Catharina; Casadellà, Maria; Noguera-Julian, Marc; Paredes, Roger; Källander, Clas F. R.; Sönnerborg, Anders // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

  Background: A sensitive, phenotypic reverse transcriptase (RT)-based drug susceptibility assay for the detection of etravirine (ETR) resistance in patient isolates was developed and compared with the results from direct sequencing and ultra-deep pyrosequencing (UDPS). Methods: Samples were...

• MODERN NNRTI REGIMENS CAN BE EFFECTIVE WITH 85% ADHERENCE. Carter, Michael // HIV Australia;Jul2015, Vol. 13 Issue 2, p54 

  The article presents a discussion on the effectiveness of non-nucleoside reverse transcriptase inhibitor (NNRTI) as treatment for HIV infection, adapted from the website aidsmap.com.

• Three NNRTI-sparing regimens equally effective as first-line HIV treatment.  // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p40 

  The article discusses a study, led by Raphael Landovitz and presented at the 2014 Conference on Retroviruses and Opportunistic Infections (CROI) in Massachusetts, on the equal effectiveness of regimens without non-nucleoside reverse transcriptase inhibitors (NNRTI) as first-line HIV treatment.

Read the Article